Fast Track designation underscores the potential for ADRX-0706 to address the high unmet need in advanced cervical cancer SAN DIEGO, May 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies...
Read More Details
Finally We wish PressBee provided you with enough information of ( Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer )
Also on site :
- Kremlin comments on ceasefire plans after Ukrainian drone strikes
- India-Pakistan deadly fighting forces airlines to re-route, cancel flights
- Bitcoin consolidates above a key level as all-time highs continue to be in sight